Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

681. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. (Abstract)

"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Adipose tissue expresses cytokines that inhibit insulin signalling pathways in liver and muscle. Obesity also results in impairment of endothelium-dependent vasodilatation in response to insulin. We propose a vasoregulatory role for local deposits of fat around the origin of arterioles supplying skeletal muscle. Isolated first-order arterioles from rat cremaster muscle are under dual (...) regulation by insulin, which activates both endothelin-1 mediated vasoconstriction and nitric-oxide-mediated vasodilatation. In obese rat arterioles, insulin-stimulated NO synthesis is impaired, resulting in unopposed vasoconstriction. We propose that this vasoconstriction is the consequence of production of the adipocytokine tumour necrosis factor alpha from the cuff of fat seen surrounding the origin of the arteriole in obese rats--a depot to which we ascribe a specialist vasoregulatory role. We

2005 Lancet

682. insulin glargine (rDNA origin)

insulin glargine (rDNA origin) CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION INSULIN GLARGINE (Lantus® - Aventis Pharma Inc.) Description: Insulin glargine is an insulin analog indicated for once-daily subcutaneous administration for patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends (...) that insulin glargine not be listed. Dosage Forms: 100 IU/mL, 10 mL vial Reasons for the recommendation: 1. The committee considered 20 open-label randomized controlled trials (RCTs) lasting from 4 to 52 weeks that compared insulin glargine with NPH insulin, of which 11 were conducted in Type 1 diabetes and 9 in Type 2 diabetes. One trial compared insulin glargine with insulin ultralente in Type 1 diabetes. The studies did not find statistically or clinically significant differences between insulin

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

683. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. (Abstract)

Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Fast-food consumption has increased greatly in the USA during the past three decades. However, the effect of fast food on risk of obesity and type 2 diabetes has received little attention. We aimed to investigate the association between reported fast-food habits and changes in bodyweight and insulin resistance over a 15-year period in the USA.Participants for the CARDIA study included 3031 (...) young (age 18-30 years in 1985-86) black and white adults who were followed up with repeated dietary assessment. We used multiple linear regression models to investigate the association of frequency of fast-food restaurant visits (fast-food frequency) at baseline and follow-up with 15-year changes in bodyweight and the homoeostasis model (HOMA) for insulin resistance.Fast-food frequency was lowest for white women (about 1.3 times per week) compared with the other ethnic-sex groups (about twice

2005 Lancet

684. Endothelial inflammation in insulin resistance. (Abstract)

Endothelial inflammation in insulin resistance. Type 2 diabetes and attendant cardiovascular morbidity are becoming major health concerns globally. Obesity-related type 2 diabetes is rapidly rising in prevalence, probably largely because of increased longevity and sedentary lifestyles. Insulin resistance and type 2 diabetes are associated with increased coronary heart disease, but the severity of glycaemia during the diabetic phase can only to a minor extent explain the increased risk (...) . Increased levels of the acute-phase inflammatory marker, C-reactive protein (CRP), are related to insulin resistance and the metabolic syndrome, suggesting a role for chronic low-grade inflammation. CRP levels might predict the development of type 2 diabetes.Subodh Verma and associates (Circulation 2004; 109: 2058-67) recently showed that CRP attenuates the survival, differentiation, and function of endothelial progenitor cells, partly by CRP reducing expression of endothelial nitric-oxide synthase

2005 Lancet

685. Premature birth and later insulin resistance. Full Text available with Trip Pro

Premature birth and later insulin resistance. Term infants who are small for gestational age appear prone to the development of insulin resistance during childhood. We hypothesized that insulin resistance, a marker of type 2 diabetes mellitus, would be prevalent among children who had been born prematurely, irrespective of whether they were appropriate for gestational age or small for gestational age.Seventy-two healthy prepubertal children 4 to 10 years of age were studied: 50 who had been (...) born prematurely (32 weeks' gestation or less), including 38 with a birth weight that was appropriate for gestational age (above the 10th percentile) and 12 with a birth weight that was low (i.e., who were small) for gestational age, and 22 control subjects (at least 37 weeks' gestation, with a birth weight above the 10th percentile). Insulin sensitivity was measured with the use of paired insulin and glucose data obtained by frequent measurements during intravenous glucose-tolerance tests.Children

2004 NEJM

686. Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Full Text available with Trip Pro

Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Article Text Treatment Training in flexible

2004 Evidence-Based Nursing

687. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. (Abstract)

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. Liposuction has been proposed as a potential treatment for the metabolic complications of obesity. We evaluated the effect of large-volume abdominal liposuction on metabolic risk factors for coronary heart disease in women with abdominal obesity.We evaluated the insulin sensitivity of liver, skeletal muscle, and adipose tissue (with a euglycemic-hyperinsulinemic clamp procedure and isotope-tracer (...) with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P<0.001). Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C

2004 NEJM

688. Best practice guideline for the subcutaneous administration of insulin in adults with type 2 diabetes.

Best practice guideline for the subcutaneous administration of insulin in adults with type 2 diabetes. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines

2004 Registered Nurses' Association of Ontario

689. Coronary vasomotor abnormalities in insulin-resistant individuals. (Abstract)

Coronary vasomotor abnormalities in insulin-resistant individuals. Insulin resistance is a metabolic spectrum that progresses from hyperinsulinemia to the metabolic syndrome, impaired glucose tolerance, and finally type 2 diabetes mellitus. It is unclear when vascular abnormalities begin in this spectrum of metabolic effects.To evaluate the association of insulin resistance with the presence and reversibility of coronary vasomotor abnormalities in young adults at low cardiovascular risk.Cross (...) -sectional study followed by prospective, open-label treatment study.University hospital.50 insulin-resistant and 22 insulin-sensitive, age-matched Mexican-American participants without glucose intolerance or traditional risk factors for or evidence of coronary artery disease.3 months of thiazolidinedione therapy for 25 insulin-resistant patients.Glucose infusion rate in response to insulin infusion was used to define insulin resistance (glucose infusion rate < or = 4.00 mg/kg of body weight per minute

2004 Annals of Internal Medicine

690. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. Full Text available with Trip Pro

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. Insulin resistance appears to be the best predictor of the development of diabetes in the children of patients with type 2 diabetes, but the mechanism responsible is unknown.We performed hyperinsulinemic-euglycemic clamp studies in combination with infusions of [6,6-(2)H(2)]glucose in healthy, young, lean, insulin-resistant offspring of patients with type 2 diabetes and insulin-sensitive control (...) subjects matched for age, height, weight, and physical activity to assess the sensitivity of liver and muscle to insulin. Proton ((1)H) magnetic resonance spectroscopy studies were performed to measure intramyocellular lipid and intrahepatic triglyceride content. Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring the rates of [(2)H(5)]glycerol turnover in combination with microdialysis measurements of glycerol release from subcutaneous fat. We performed (31)P magnetic

2004 NEJM

691. Insulinomas and expression of an insulin splice variant. (Abstract)

Insulinomas and expression of an insulin splice variant. Insulinomas are beta-cell tumours characterised by uncontrolled insulin secretion even in the presence of hypoglycaemia. However, the mechanisms allowing such excessive insulin secretion are not known. Insulin secretion can occur only when the beta-cell insulin stores have been replenished by insulin biosynthesis, which is mainly controlled by translation. Such specific translational regulation often involves the 5' untranslated region (...) . We have identified an insulin splice variant in isolated human pancreatic islets of non-diabetic donors that retains 26 bp of intron 1 and thereby changes the 5' untranslated region, but leaves the coding region unchanged. This splice variant has increased translation efficiency in vitro and in vivo compared with native insulin mRNA. However, splice variant expression is less than 1% of native insulin mRNA in normal islets.To test whether this splice variant is involved in insulin production

2004 Lancet

692. [Effect of a two-week program of individually monitored physical activity on insulin resistance in obese non-insulin-dependent diabetics]. (Abstract)

[Effect of a two-week program of individually monitored physical activity on insulin resistance in obese non-insulin-dependent diabetics]. It is well known that under the influence of regular, individually measured aerobic physical activity, it is possible to raise the biological efficiency of insulin by several mechanisms: by increasing the number of insulin receptors, their sensitivity and efficiency, as well as by increasing glucose transporters GLUT-4 on the level of cell membrane. The aim (...) of this research was to examine whether decreased insulin resistance could be achieved under the influence of the program of individually measured aerobic physical activity in the 2-week period, in the obese type 2 diabetes patients with the increased aerobic capacity (VO2)max. In 10 type 2 diabetes patients 47.6 +/- 4.6 years of age (group E), in the 14-days period, program of aerobic training was applied (10 sessions--35 min session of walking on treadmill, intensity 60.8 +/- 5.7% (VO2)max, frequency 5 times

2004 Vojnosanitetski pregled

693. BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes

BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes Best Practice Guideline for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes Nursing Best Practice Guideline Shaping the future of Nursing June 2004Greetings from Doris Grinspun Executive Director Registered Nurses Association of Ontario It is with great excitement that the Registered Nurses Association of Ontario (RNAO) disseminates this nursing best practice guideline to you. Evidence (...) Administration of Insulin in Adults with Type 2 Diabetes Guideline Development Panel Members Declarations of interest and confidentiality were made by all members of the guideline development panel. Further details are available from the Registered Nurses Association of Ontario. Anna Brundage, RN, BHSc(N), CDE Team Leader Manager TRIDEC Sunnybrook and Women’s College Health Sciences Centre Toronto, Ontario Ceilia Ayotte, RN, CDE Diabetes Educator Peterborough Regional Health Centre Peterborough, Ontario

2004 Registered Nurses' Association of Ontario

694. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Full Text available with Trip Pro

Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Dehydroepiandrosterone (DHEA) administration has been shown to reduce accumulation of abdominal visceral fat and protect against insulin resistance in laboratory animals, but it is not known whether DHEA decreases abdominal obesity in humans. DHEA is widely available as a dietary supplement without a prescription.To determine whether DHEA replacement therapy decreases abdominal fat (...) and improves insulin action in elderly persons.Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from June 2001 to February 2004.Fifty-six elderly persons (28 women and 28 men aged 71 [range, 65-78] years) with age-related decrease in DHEA level.Participants were randomly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months.The primary outcome measures were 6-month change in visceral and subcutaneous abdominal fat measured by magnetic

2004 JAMA Controlled trial quality: predicted high

695. Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes

Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Vora A C, Saleem (...) T M, Polomano R C, Eddinger V L, Hollenbeak C S, Girdharry D T, Joshi R, Martin D, Gabbay R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed an insulin infusion glycaemic control protocol (IGCP

2004 NHS Economic Evaluation Database.

696. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Warren E, Weatherley-Jones E, Chilcott J, Beverley C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment 2004; 8(45): 1-72 Authors' objectives The aim of this review was to evaluate the use of insulin glargine in its licensed basal-bolus indication in terms of both clinical and cost-effectiveness. Authors' conclusions The evidence suggests that, compared with NPH insulin, insulin

2004 Health Technology Assessment (HTA) Database.

697. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technology Assessment 2004; 8(43): 1-186 Authors' objectives This systematic review examines the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) using insulin pumps compared with multiple daily injections (MDI) for diabetes. Authors' conclusions When compared with optimised MDI, CSII results

2004 Health Technology Assessment (HTA) Database.

698. Insulin detemir for diabetes mellitus

Insulin detemir for diabetes mellitus Insulin detemir for diabetes mellitus Insulin detemir for diabetes mellitus Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Insulin detemir for diabetes mellitus. Ottawa (...) : Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of insulin detemir (Trade Name: Levemir, manufactured by Novo Nordisk) for the management of type 1 (insulin dependent) diabetes mellitus (DM) and type 2 (non-insulin dependent) DM. Authors' conclusions Insulin detemir is a new long-acting insulin analogue for the treatment of type 1 and type 2 DM. It does not improve HbA1c control or reduce overall

2004 Health Technology Assessment (HTA) Database.

699. Insulin glargine for type 2 diabetes

Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Insulin glargine for type 2 diabetes. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of insulin glargine (Trade Mark: Lantus) - a biosynthetic, long-acting human insulin analogue - to treat type 2 diabetes. Authors' conclusions Patients who have adequate glycemic control and minimal hypoglycemic events with NPH insulin will likely not derive additional benefit from insulin glargine (in most studies, insulin glargine did not significantly reduce fasting

2004 Health Technology Assessment (HTA) Database.

700. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK

Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Shearer A, Bagust A, Sanderson D, Heller S, Roberts S Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A structured treatment and teaching programme (STTP), combining dietary freedom with insulin adjustment for Type 1 diabetes, was evaluated. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population

2004 NHS Economic Evaluation Database.